NXL (Nexalin Technology) Stock Based Compensation: $2.80 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NXL Nexalin Technology Inc NXL
38 GF Score
Price $0.33
GF Value $0.66
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Nexalin Technology Stock Based Compensation?

Nexalin Technology NXL +0.18% 38 Stock Based Compensation is $2.80 Mil as of Jun. 2026. GuruFocus rates NXL with a GF Score™ of 38/100 and a GF Value™ of $0.66 (Possible Value Trap). The stock has 7 warning signs investors should review.

Nexalin Technology's Stock Based Compensation for the three months ended in Jun. 2026 was $0.41 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was $2.80 Mil.

Nexalin Technology Stock Based Compensation Related Terms

Nexalin Technology Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Nexalin Technology's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalin Technology Stock Based Compensation Chart

Nexalin Technology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 4.48 0.27 2.41 3.56 3.12

Nexalin Technology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 1.08 0.83 0.48 0.41
NXL
38GF Score
Nexalin Technology Inc NXL
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nexalin Technology Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.80 Mil.

What does a Stock Based Compensation of $2.80 Mil mean?
Nexalin Technology (NXL) has a Stock Based Compensation of $2.80 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Nexalin Technology and its competitors.
Is Nexalin Technology's Stock Based Compensation too high?
Nexalin Technology's current Stock Based Compensation is $2.80 Mil. Overall, Nexalin Technology has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nexalin Technology's Stock Based Compensation compare to ICCM and ADGM?
Nexalin Technology's Stock Based Compensation of $2.80 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Nexalin Technology and its competitors. Nexalin Technology's current Stock Based Compensation is $2.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalin Technology stock overvalued right now?
Based on GuruFocus' analysis, Nexalin Technology (NXL) is currently considered Possible Value Trap. The stock's GF Value™ is $0.66, compared to a current price of $0.33 — trading 49.6% below its estimated fair value. The current Stock Based Compensation is $2.80 Mil. Nexalin Technology's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Nexalin Technology (NXL), the current Stock Based Compensation is $2.80 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nexalin Technology (NXL) Overvalued in 2026?

Based on GuruFocus' analysis, Nexalin Technology stock appears to be undervalued. The current stock price of $0.33 is trading 49.6% below its estimated GF Value™ of $0.66. GuruFocus considers Nexalin Technology to be Possible Value Trap.

Key valuation signals for NXL:

  • Stock Based Compensation: $2.80 Mil
  • GF Value™: $0.66 vs. price of $0.33 (49.6% below fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the NXL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nexalin Technology Business Description

Address 1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
38GF Score

Get the complete analysis for NXL

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.66
GF Value